Alexza lands European partner for stymied agitation therapy

With the FDA blocking an approval for Alexza's ($ALXA) anti-agitation treatment Adasuve (AZ-004), the U.S. biotech has forged ahead with a European pact that brings a $10 million upfront payment with it. Spain's Grupo Ferrer also committed to a set of milestones on Adasuve as Alexza takes on responsibility for filing the treatment, which uses an inhaler, with the EMA. Regulators at the FDA rejected the therapy last fall, citing adverse events in early-stage studies. Story

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.